Patent intelligence · AU
AU 2021323364
Antimicrobial peptidomimetics
Antimicrobial peptidomimetics
Patent details — AU 2021323364
- Jurisdiction
- AU
- Status
- granted
- Grant date
- Mar 30, 2023
- Expiration
- Mar 25, 2043
- CPC classes
- A61K/3800, A61P 31/ 04 A I, A61P/3104
Quick answer
AU 2021323364 (Antimicrobial peptidomimetics) is held by BASILEA PHARMACEUTICA INTERNATIONAL AG ALLSCHWIL [CH]. Status: granted. Granted Mar 30, 2023. Expires Mar 25, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K/3800, A61P 31/ 04 A I, A61P/3104
More from BASILEA PHARMACEUTICA INTERNATIONAL AG ALLSCHWIL [CH]
Related pharmaceutical patents in our USPTO index.
-
AU 2024384453
CITRATE COORDINATION COMPLEX OF AN ORALLY-DELIVERED BETA-LACTAMASE INHIBITOR AND USES THEREOF
granted -
PT 3886798
COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF
granted -
US 20260042800
ANTIMICROBIAL PEPTIDOMIMETICS
granted -
WO 2025114603
COMBINAISONS PHARMACEUTIQUES DESTINÉES À ÊTRE UTILISÉES DANS LE TRAITEMENT D'INFECTIONS FONGIQUES
granted -
WO 2024094329
PRÉPARATION DE CAPSULE SOUS EMBALLAGE COQUE CONTENANT DU SULFATE D'ISAVUCONAZONIUM
granted -
CA 3268414
MÉTHODES DE TRAITEMENT D'INFECTIONS AVEC BACTÉRIÉMIE À STAPHYLOCOCCUS AUREUS
granted -
AU 2022323463
ANTIMICROBIAL PEPTIDOMIMETICS
granted -
AR 127448
DERIVADOS DE BENZO[H]QUINAZOLIN-4-AMINA PARA EL TRATAMIENTO DEL CÁNCER
granted
Frequently asked questions
What is US patent 2021323364?
AU 2021323364 (Antimicrobial peptidomimetics) is held by BASILEA PHARMACEUTICA INTERNATIONAL AG ALLSCHWIL [CH]. Status: granted. Granted Mar 30, 2023. Expires Mar 25, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns AU 2021323364?
BASILEA PHARMACEUTICA INTERNATIONAL AG ALLSCHWIL [CH] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does AU 2021323364 expire?
Our index shows an expiration date of Mar 25, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.